The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | RESONATE, RESONATE-2 and HELIOS: three major clinical trials in CLL research
Thomas Kipps, MD, PhD, from University of California, San Diego, CA, discusses the results from three clinical trials in this interview, all of which evaluate treatments for chronic lymphocytic leukemia (CLL). The first trial, RESONATE (NCT01578707), evaluated whether treatment with ibrutinib was superior to ofatumumab in treating patients with relapsed or refractory CLL. The second trial, RESONATE-2 (NCT01722487) was a Phase II study evaluating whether ibrutinib was superior to chlorambucil in treating CLL, and the third trial, HELIOS (NCT01611090), was a Phase III study evaluating the effectiveness of a bendamustine and ibrutinib combination in treating CLL. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
